Friday, July 10, 2026

pharma · Atopic Dermatitis · Acne Vulgaris

UAS Pharmaceuticals Pty

UAS Pharmaceuticals Pty clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Castle Hill, AU HQ
2000 Founded
44 Employees
TGA registrant Type
Company details
Status
Public
HQ
Castle Hill, AU
Founded
2000
Employees
44
Programs
4
Drugs
7
Patents
0
Intelligence · Clinical Programs

UAS Pharmaceuticals Pty projects

4 ClinicalTrials.gov programs sponsored by UAS Pharmaceuticals Pty.

UAS Pharmaceuticals Pty has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Adapalene 0.3% / BPO 2.5% gel

    Galderma Australia Pty Ltd

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial
  2. Nemolizumab

    Galderma Australia Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial
  3. Nemolizumab

    Galderma Australia Pty Ltd

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial
  4. Nemolizumab

    Galderma Australia Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does UAS Pharmaceuticals Pty have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.